EU H2020 Project "LAA-START (Left Atrial Appendage Electrical Isolation via Bio-photonic Optical..)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/220033/index.html
-1	/open-h2020/projects/226468/index.html
-2	/open-consip/fornitori/2019/profilo-01809291204/index.html
-3	/open-h2020/projects/218500/index.html
-4	/open-fp7/projects/197067/index.html
-5	/open-h2020/projects/214224/index.html
-6	/open-h2020/projects/205529/deliverables.html
-7	/open-h2020/projects/199167/index.html

LAA-START project word cloud

Explore the words cloud of the LAA-START project. It provides you a very rough idea of what is the project "LAA-START" about.

heart data healthcare efficacy clots uk catheter permanently stream health initial muscle irregular flow procedure rates markets therapy total arrhythmia services ce shut 30 13 aurigen entering appendage patients treating fit cardiac symptomatic human complete atrial medical financially clinical tissue doubled causing first prevent million electrical safety surgical isolation device left implants paf stroke abnormal ablation caused opportunity 72 incapable 2020 destroys line doubles filter germany q3 medication shot time laa least italy fda surgery 5bn enter heartbeat contraction regulatory classified occlusion billion implant blood amounting approximately persistent redo resistant af wasted risk fti opening fitting too works hours market certification mechanically fibrillation minimally invasive pulses isolates electrically france

Project "LAA-START" data sheet

The following table provides information about the project.

Coordinator	AURIGEN MEDICAL LIMITED Organization address address: 18 CHURCHWELL SQUARE city: DUBLIN postcode: DUBLIN 13 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Total cost	5˙012˙590 €
EC max contribution	2˙999˙998 € (60%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-EIC-FTI-2018-2020
Funding Scheme	IA
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2020-12-31

#	participants	country	role	EC contrib. [€]
1	AURIGEN MEDICAL LIMITED	IE (DUBLIN)	coordinator	1˙115˙458.00
2	TELEFLEX MEDICAL EUROPE LIMITED	IE (ATHLONE CO. WESTMEATH)	participant	953˙470.00
3	UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK	IE (Cork)	participant	516˙948.00
4	MEDIBRANE LTD	IL (ROSH HAAYIN)	participant	334˙600.00
5	CESKE VYSOKE UCENI TECHNICKE V PRAZE	CZ (PRAHA)	participant	79˙522.00

AURIGEN MEDICAL LIMITED

IE (DUBLIN)

coordinator

1˙115˙458.00

TELEFLEX MEDICAL EUROPE LIMITED

IE (ATHLONE CO. WESTMEATH)

participant

953˙470.00

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

IE (Cork)

participant

516˙948.00

MEDIBRANE LTD

IL (ROSH HAAYIN)

participant

334˙600.00

CESKE VYSOKE UCENI TECHNICKE V PRAZE

CZ (PRAHA)

participant

79˙522.00

Project objective

Atrial Fibrillation (AF) is an irregular heartbeat caused by abnormal electrical activity in the heart, that can lead to blood clots with high risk of stroke and heart failure. There are 10.7 million AF patients across Europe and the US, 3.6 million are classified as having Persistent AF (PAF), they are highly symptomatic and medication resistant. Surgical electrical therapy (catheter ablation) destroys heart tissue causing the abnormal electrical pulses. For PAF patients, this works only 30% of the time. Approximately 72% of PAF patients require at least one redo procedure, amounting to €13.5 billion in wasted healthcare costs. Success rates are doubled if electrical activity in a part of the heart “the Left Atrial Appendage” (LAA), is shut down. But this increases stroke risk from blood clots as the LAA is now incapable of muscle contraction to maintain blood flow. LAA implants, “occlusion devices” fit across the opening of the LAA to filter the blood and prevent clots from entering the blood stream. However, fitting an occlusion device during the same procedure as LAA electrical isolation doubles procedure time (to 7 hours) making it non-financially viable for health services and too high risk for patients. AuriGen Medical have developed a unique, minimally invasive cardiac implant which permanently electrically and mechanically isolates the LAA in a one-shot procedure: treating both the stroke and arrhythmia risk associated with PAF with no increase in surgery time. This multi-partner FTI project will complete product development in line with the regulatory development pathway for medical devices for first in human safety and efficacy clinical studies required for CE certification and contributing to FDA clinical data requirements. The total market opportunity is $5bn/yr market opportunity across the EU and US. AuriGen will enter the market directly in the initial target European markets (Germany, France, Italy and UK) during Q3 2020.

Deliverables

List of deliverables.
Clinical Affairs Director Appointed	Other	2020-04-02 09:09:54
Biostatistician Appointed	Other	2020-04-02 09:10:11
Manufacturing Engineer Appointed	Other	2020-04-02 09:10:03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LAA-START" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LAA-START" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)